| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6214815 | JANSSEN PHARMS | Triphasic oral contraceptive |
Jun, 2019
(4 years ago) | |
|
US6214815 (Pediatric) | JANSSEN PHARMS | Triphasic oral contraceptive |
Dec, 2019
(4 years ago) | |
Ortho Tri-Cyclen Lo is owned by Janssen Pharms.
Ortho Tri-Cyclen Lo contains Ethinyl Estradiol; Norgestimate.
Ortho Tri-Cyclen Lo has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Ortho Tri-Cyclen Lo are:
- US6214815
- US6214815*PED
Ortho Tri-Cyclen Lo was authorised for market use on 22 August, 2002.
Ortho Tri-Cyclen Lo is available in tablet;oral-28 dosage forms.
Ortho Tri-Cyclen Lo can be used as contraception.
The generics of Ortho Tri-Cyclen Lo are possible to be released after 09 December, 2019.
Drugs and Companies using ETHINYL ESTRADIOL; NORGESTIMATE ingredient
Market Authorisation Date: 22 August, 2002
Treatment: Contraception
Dosage: TABLET;ORAL-28
How can I launch a generic of ORTHO TRI-CYCLEN LO before it's drug patent expiration?
More Information on Dosage
ORTHO TRI-CYCLEN LO family patents
